CD30 Expression and Its Functions during the Disease Progression of Adult T-Cell Leukemia/Lymphoma

CD30, a member of the tumor necrosis factor receptor superfamily, plays roles in pro-survival signal induction and cell proliferation in peripheral T-cell lymphoma (PTCL) and adult T-cell leukemia/lymphoma (ATL). Previous studies have identified the functional roles of CD30 in CD30-expressing malignant lymphomas, not only PTCL and ATL, but also Hodgkin lymphoma (HL), anaplastic large cell lymphoma (ALCL), and a portion of diffuse large B-cell lymphoma (DLBCL). CD30 expression is often observed in virus-infected cells such as human T-cell leukemia virus type 1 (HTLV-1). HTLV-1 is capable of immortalizing lymphocytes and producing malignancy. Some ATL cases caused by HTLV-1 infection overexpress CD30. However, the molecular mechanism-based relationship between CD30 expression and HTLV-1 infection or ATL progression is unclear. Recent findings have revealed super-enhancer-mediated overexpression at the CD30 locus, CD30 signaling via trogocytosis, and CD30 signaling-induced lymphomagenesis in vivo. Successful anti-CD30 antibody-drug conjugate (ADC) therapy for HL, ALCL, and PTCL supports the biological significance of CD30 in these lymphomas. In this review, we discuss the roles of CD30 overexpression and its functions during ATL progression.

Automated summary

CD30, a member of the tumor necrosis factor receptor superfamily, plays important roles in the survival and proliferation of peripheral T-cell lymphoma (PTCL) and adult T-cell leukemia/lymphoma (ATL). Its overexpression is observed in various lymphomas, including PTCL, ATL, Hodgkin lymphoma (HL), anaplastic large cell lymphoma (ALCL), and a portion of diffuse large B-cell lymphoma (DLBCL). CD30 expression is often associated with HTLV-1 infection, and recent studies have shed light on the molecular mechanisms underlying the relationship between CD30 expression and HTLV-1 infection or ATL progression. The successful use of anti-CD30 antibody-drug conjugate (ADC) therapy in treating HL, ALCL, and PTCL further highlights the significance of CD30 in these lymphomas.